Metro International Biotech
CompanyUnited States
Metro International Biotech develops 2 assets, the furthest in phase 2 (MIB-626 in Alzheimer's disease). Mostly small molecule acting on oxidative phosphorylation, sirtuin signalling and NAD+ metabolism; based in the United States.
- 2
- Assets
- Furthest
- Phase 2
- 5
- Trials
- 0
- Signals
Pipeline
2Oral beta-nicotinamide mononucleotide NAD+ precursor enhancing NAD+ biosynthesis and mitochondrial function.
Phase 2, Small molecule, Oxidative phosphorylation, Mitochondrial biogenesis (PGC-1α), Alzheimer's disease, Covid19
Oral next-generation NAD+ precursor boosting cellular NAD+ levels.
Phase 1, Small molecule, Oxidative phosphorylation, Sirtuin signalling, acute kidney injury
Full company profiles: pipeline, trials, funding and people.
See ProIn the full profile
- Evidence behind the mechanisms6
- Trials5
- Similar companies6
Updated 7 Oct 2026 · 13 sources